Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization

El-Agnaf, M.; McCoy, Cathy; Ong, Young-Lee; Eswedi, Abdul-Hakeem; Black, Barbra; Ramadan, Khaled M. A.

doi:10.1080/10428190701509780

Cited by 9 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRS following rituximab is known for dyspnea, bronchospasm, hypoxia, fever, chills, rigors and angioedema. Patients with bulky disease or >25×10 9 /l lymphocytes, mostly patients with CLL, have a higher probability of CRS and should be monitored carefully (49,50). A lower infusion rate or dividing the dose over 2 days should be considered for these patients.…”

Section: Resultsmentioning

confidence: 99%

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

Background: Patients with cancer who are treated with monoclonal antibodies are at risk for developing infusion reactions. However, for some monoclonal antibodies, the incidence of infusion reactions is low or can be lowered by the use of adequate premedication schedules. It is often feasible to increase the infusion rate/lower the post-administration observation time. This review gives an overview of infusion reactions and the possibility of accelerating infusion rates. Materials and Methods: Data on infusion reactions and infusion rates for all monoclonal antibodies that are licensed in the European Union for treatment of solid tumors or hematological malignancies, found by a literature search, were included in this review. Results: For 11 out of the 21 monoclonal antibodies data exceeding the registration text were found and described. Faster infusion schedules are possible for bevacizumab, ipilimumab, nivolumab, panitimumab, and rituximab. Conclusion: We propose optimal infusion schedules for each drug.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This was because patients who developed adverse reactions could not be segregated based on their diagnoses. Most studies 1,2,10–14,18–22 stated the type of chemotherapy regimen used except one study 3 …”

Section: Resultsmentioning

confidence: 99%

“…In response to these challenges, many medical centres across the world including the USA and Canada, Europe, Middle East and Asia have conducted research studies 1,3,10,12–25 to evaluate the feasibility and safety of rapid rituximab infusion. To date, only one study has identified that rapid infusion is as effective as conventional rate infusion in patients with diffuse large B cell lymphoma 11 .…”

Section: Introductionmentioning

confidence: 99%

Safety of rapid rituximab infusion in adult cancer patients: A systematic review

Lang

Hagger

Pearson

2011

Int J of Nursing Practice

View full text Add to dashboard Cite

The purpose of this study is to critically appraise, synthesize and present the best available evidence related to the safety of rapid rituximab infusion in adult non-Hodgkin lymphoma and chronic lymphocytic leukaemia patients. Data are from published and unpublished studies from electronic databases, grey literature and reference lists. The studies that met the inclusion criteria were critically appraised by two independent reviewers for methodological validity using standardized critical appraisal instruments. Proportional meta-analysis based on DerSimonian-Laird weights using a random effects model was used for statistical pooling through Stats Direct. Heterogeneity is assessed using Cochran Q. When statistical pooling is not possible, the findings were presented in narrative summary. Rapid rituximab infusion is safe for non-Hodgkin lymphoma patients at a 90 min regimen. However, there is insufficient evidence to support rapid rituximab infusions for chronic lymphocytic leukaemia patients.

show abstract

“…The incidence of infusion‐related reactions during rapid infusion administration is comparable to standard infusion rates in patients who successfully tolerate their first infusion . Limited reports of rapid infusions in small numbers of children with autoimmune hemolytic anemia (AIHA), chronic immune thrombocytopenia (ITP), and following hematopoietic stem cell transplant demonstrate similar safety and efficacy data as seen in adult studies .…”

Section: Introductionmentioning

confidence: 99%

“…No grade 3 or 4 reactions and no increase in minor infusion reactions were observed . Further data involving rapid infusion of rituximab given over 60–90 minutes has demonstrated the safety and tolerability of this approach, prompting the approval of FDA 90‐min infusion in the package labeling for patients receiving glucocorticoid‐based treatment regimens …”

Section: Introductionmentioning

confidence: 99%

Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders

Bernhardt

Guzman

Grimes

et al. 2017

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Traditional administration of rituximab requires careful titration and may involve many hours to minimize the risk of reactions. The objective of this study was to evaluate the safety of rapid infusions of rituximab in a pilot group of children with hematologic, oncologic, and rheumatologic disorders, and to determine the incidence of rate-related infusion reactions. Twenty patients enrolled in the study. All patients tolerated the rapid infusion of rituximab and no patient had an infusionrelated reaction. We conclude that rapid infusions of rituximab are well tolerated and safe in our pilot group of patients.

show abstract

Infusion of rituximab over 90 minutes on an out-patient basis is safe and improves resource utilization

Cited by 9 publications

References 13 publications

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment

Safety of rapid rituximab infusion in adult cancer patients: A systematic review

Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders

Contact Info

Product

Resources

About